Professional activities

Conference Roles

From artemisinin to tetraoxane-based antimalarial drug candidates, by Invitation (25th Annual Groupement des Pharmacochimistes de l’Arc Atlantique (GP2A), Liverpool John Moore's University, 2017)
Antimalarial Peroxide Probe and Candidate Synthesis, Keynote/Plenary by Invitation (Peakdale molecular 'synthesis in drug discovery and development' 4th symposium, Liverpool Hope University, 2016)
From artemisinin to a tetraoxane-based antimalarial drug candidate that circumvents K13- dependent clinical artemisinin resistance , Keynote/Plenary by Invitation (Bioactive Natural Products: translating promise into practice, at St Catherine’s College, Oxford University, 2016)
Endoperoxide Antimalarial Drug Development and Mechanism of Action, by Invitation (New Horizons and Emerging Biomedical Challenges for Biophysics, University of Liverpool, 2016)
A tetraoxane-based antimalarial drug candidate that circumvents PfKelch 13-dependent artemisinin resistance, Keynote/Plenary by Invitation (13th Asia Pacific Federation of Pharmacologists (APFP) 2016, Bangkok Thailand, 2016)
E209, A Novel Tetraoxane Antimalarial Candidate, by Invitation (SCI Academic Drug Discovery 3, London, 2015)
From Synthetic Endoperoxide Drug Candidates to Dual Acting Peroxide Based Hybrids, by Invitation (Shanghai Institution of Organic Chemistry, Shanghai, China, 2014)
Third Generation Tetraoxane Antimalarials, by Invitation (Institution of Biomedical Sciences, Fudan, University, Shanghai, China, 2014)
Development of a new generation of antimalaria lead quinolones targeting the mitochondrial respiratory pathway for the treatment and prophylaxis of uncomplicated malaria, Keynote/Plenary by Invitation (London School of Tropical medicine Hygiene, Emerging Paradigms in Anti-infective Drug Design, 17th Sept, , 2012)
Antimalarial Drug Discovery at the University of Liverpool, by Invitation (3rd Annual Georgia Nanotechnology & Infectious Diseases Symposium, Mercer University, Atlanta , USA, 2012)
From Candidate Selection of Synthetic Peroxides to Lead Optimisation of Quinolone Inhibitors of PfNDH2, by Invitation (UCL (London) Dept Seminar, 2012)
Antimalarial Drug Discovery at Liverpool, by Invitation (GSK Tres Cantos,Madrid, Spain, 2012)
Antimalarial Tetraoxanes; Candidate selection and back-up programme, by Invitation (EU FP6, 2011)
Drug Development of 1,2,4,5-Teraoxanes, by Invitation (RSC British High Commission, 2011)
From candidate selection of the first Tetraoxane Drug Candidate RKA 182 to the Discovery of Picomola, Keynote/Plenary by Invitation (RSC, London School of Tropical Medicine and Hygiene, 2010)
Antimalarial Drug Discovery at the University of Liverpool, by Invitation (Pfizer, Sandwich, Kent, 2010)
From candidate selection of the first Tetraoxane Drug Candidate RKA 182 and Appropriate Back-ups, Keynote/Plenary by Invitation (EFMC Sponsored 2nd National Conference on Medicinal Chemistry, Coimbra, Portugal, 2010)
Update on Tetraoxane Drug Development, by Invitation (St Georges Hospital, London, 2010)
Synthesis in Medicinal Chemistry, Keynote/Plenary by Invitation (Peakdale Molecular Symposium, Manchester, 2010)
Medicinal Chemistry of Quinoline and Peroxide Antimalarials, by Invitation (Laboratoire de Chimie de Coordination du CNRS, 205 route de Narbonne, 31077 Toulouse Cedex 4, France, 2010)
Antimalarial Drug Discovery in Academia; Discovery of Isoquine, FAQ4 and RKA182 , Keynote/Plenary by Invitation (British High Commission and RSC , Singapore, 2010)
Antimalarial Drug Discovery in Academia , Keynote/Plenary by Invitation (1st RSC China-UK Symposium on Medicinal Chemistry, Shanghai, China, 2009)
Synthetic Approaches to Endoperoxide Antimalarials, by Invitation (SCI Conference orgnaised by the SCI Young Chemists Panel , 2009)
Selection of RKA 182 as the first tetraoxane antimalarial drug candidate , Keynote/Plenary by Invitation (Keystone Symposia, Breckenridge Colorado, USA, 2009)
From the Natural Herb Qinghaosu (Artemisinin) to Orally Active Synthetic Endoperoxide Antima, by Invitation (University of Bangor, 2008)
Antimalarial Chemotherapy In the 21st Century; Advances in Drugs Targeting the Hemoglobin Degradatio, by Invitation (University of Warwick, 2008)
Advances in the Medicinal Chemistry of 4-Aminoquinolines, by Invitation (ACS Conference , Boston, 2007)
From the Natural Herb Extract Quinghaosu (Artemisinin) to Orally Active Synthetic Endoperoxide Antim, by Invitation (ESB, 2007)
Recent Advances in the Development of Drugs Targeting the Hemoglobin Degradation Pathway, Keynote/Plenary by Invitation (ACS Medicinal Chemistry & Bioorganic Chemistry Foundation, 2007)
Evidence for a Common Iron Dependent Mechanism of Action for Diverse Endoperoxide Antimalarials, by Invitation (EU COST, 2006)
A 4-Aminoquinoline Antimalarial for the 21st Century , by Invitation ((IUPHAR) Congress of Pharmacology, 2006)
The Drug Hybrid Approach to Antimalarial Chemotherapy, by Invitation (ISSX, 2006)
Toward a 21st Century Replacement for Chloroquine and Amodiaquine , by Invitation (EU COST Initiative, 2005)

Examination Roles

University of Glasgow, PhD (2016)
Imperial College London, PhD (2015)
University of East Anglia, PhD (2015)
University of Cape Town South Africa, PhD (2014)
University of Leeds, PhD (2013)
Imperial College, University of London, UK, PhD (2012)
Imperial College, University of London, UK, PhD (2011)
University of Dublin, PhD (2011)
University of Cape Town South Africa, PhD (2010)
University of Montpellier (France), PhD (2010)
University of Montpellier (France), PhD (2010)
University of Manchester, PhD (2007)

Organisations I have been associated with

Eisai (2014 - present)
AWOL (LSTM) (2014 - present)
Astra Zeneca (2014 - present)
Abbvie (2015 - present)
Open Lab Foundation (GSK) (Tres Cantos) (2015 - 2016)
GSK (2010 - 2015)
Bayer (2006 - 2010)

Professional Body Memberships

American Chemical Society (ACS Division of Organic Chemistry, 2007 - 2010)
Royal Society of Chemistry (Member, 2002 - 2010)